Suppr超能文献

儿童重症IgA肾病的治疗

Treatment of severe IgA nephropathy in children.

作者信息

Andreoli S P, Bergstein J M

机构信息

Department of Pediatrics, Indiana University School of Medicine, Indianapolis.

出版信息

Pediatr Nephrol. 1989 Jul;3(3):248-53. doi: 10.1007/BF00858524.

Abstract

We treated ten children with severe IgA nephropathy (IgAN) [proteinuria greater than 1 g/day, hypertension, renal insufficiency, segmental sclerosis, crescent formation and/or glomerular basement membrane (GBM) deposition of IgA] with prednisone and azathioprine for 1 year. Following the year of therapy, seven of the ten children underwent a repeat kidney biopsy. All biopsies were scored for activity (percentage of glomeruli demonstrating crescent formation, degree of mesangial proliferation and interstitial infiltrate; maximum score = 9) and chronicity (percentage of glomeruli demonstrating fibrous crescents, segmental sclerosis, global sclerosis, and degree of tubular atrophy and interstitial fibrosis; maximum score = 12). After 1 year of therapy, the protein excretion of all the children decreased significantly (P less than 0.01) from 4,052 +/- 3,190 mg/day to 1,692 +/- 1,634 mg/day. The activity score decreased significantly (P less than 0.01) from 4.35 +/- 0.94 prior to therapy to 2.28 +/- 0.75 after therapy while the chronicity score was unchanged (5.42 +/- 1.7 vs 5.85 +/- 2.0). The percentage of glomeruli demonstrating cellular crescents decreased (P less than 0.05) from 21.2 +/- 21.7% prior to therapy to 0.94 +/- 2.4% after therapy. Mesangial deposition of IgA persisted but GBM deposition of IgA was less prominent after therapy. During the follow-up period (mean 2.6 years, range 9 months-7.5 years), one child required brief retreatment for biopsy-confirmed recurrence of active disease, two children have developed renal insufficiency due to progressive scarring in the absence of inflammation, while the remaining seven are stable. We suggest that treatment with prednisone and azathioprine may be beneficial in children with severe IgAN and that a controlled clinical trial is warranted.

摘要

我们用泼尼松和硫唑嘌呤对10名患有严重IgA肾病(IgAN)[蛋白尿大于1g/天、高血压、肾功能不全、节段性硬化、新月体形成和/或IgA在肾小球基底膜(GBM)沉积]的儿童进行了为期1年的治疗。治疗1年后,10名儿童中有7名接受了重复肾活检。所有活检均进行活性评分(显示新月体形成的肾小球百分比、系膜增生程度和间质浸润;最高评分=9)和慢性评分(显示纤维性新月体、节段性硬化、全球性硬化的肾小球百分比以及肾小管萎缩和间质纤维化程度;最高评分=12)。治疗1年后,所有儿童的蛋白排泄量从4052±3190mg/天显著降低(P<0.01)至1692±1634mg/天。活性评分从治疗前的4.35±0.94显著降低(P<0.01)至治疗后的2.28±0.75,而慢性评分未改变(5.42±1.7对5.85±2.0)。显示细胞性新月体的肾小球百分比从治疗前的21.2±21.7%降低(P<0.05)至治疗后的0.94±2.4%。治疗后IgA系膜沉积持续存在,但GBM IgA沉积不那么明显。在随访期间(平均2.6年,范围9个月至7.5年),1名儿童因活检证实活动性疾病复发需要短期再次治疗,2名儿童因无炎症情况下的进行性瘢痕形成而出现肾功能不全,其余7名儿童病情稳定。我们认为,泼尼松和硫唑嘌呤治疗可能对重症IgAN儿童有益,有必要进行一项对照临床试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验